Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All studies

RGT-61159

RGT-61159 Phase 1a/b

Rgenta Therapeutics · Phase 1 · Active, not recruiting · Enrollment 105

NCT06462183

Catalyst Primary completion. 12.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmReported safety
RGT-61159 at or below RP2Dn/r

A count stays a count. This page does not turn a count into a percent.